In a study titled: “Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies” authors, among which professor Varrassi, a well known pain expert, analyzed the activity of palmitoylethanolamide in fibromyalgia patients, who did not respond well enough on treatment with classical analgesics, such as duloxetine (DLX), administered together with pregabalin (PGB).
This is quite interesting, because the study documents thus the safety of combining palmitoylethanolamide together with such analgesics.
The study consisted of various parts, and was not controlled, but used historical controls. After 6 months of treatment, these parameters had further improvement.
Nevertheless, in the prospective observational part of the study, where PEA was administered together with the analgesics (DLX + PGB + PEA), PEA introduction after 3 months of therapeutic regimen with DLX + PGB provided an extra reduction in pain compared to patients on DLX + PGB only (p < 0.0001).
No side effects, no drug-drug interactions!
None of the patients experienced adverse side effects. This study clearly documents the absence of drug-drug interactions, and adds to the growing evidence that PEA can be easily administered in various painstates, also on top of other analgesics. Furthermore, the study also suggests that PEA can boost the analgesic effects of other analgesics, as have been indicated in the past with oxycodon and other compounds.
PEA needs more attention for pain physicians, as it is easy to add to any analgesic regime and adds also new mechanisms of action in the modern multipharmacological approach of pain.
Source: Del Giorno R1, Skaper S, Paladini A, Varrassi G, Coaccioli S. Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies.Pain Ther. 2015 Sep 3. [Epub ahead of print]